Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals logo

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Advanced Chart

Key Stats

Today's Range
$1.68
$1.90
50-Day Range
$1.31
$1.82
52-Week Range
$0.98
$9.21
Volume
437,523 shs
Average Volume
250,384 shs
Market Capitalization
$60.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
Consensus Rating
Hold

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

Onkure Therapeutics Inc (OKUR)
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Headlines

RPHM Stock Analysis - Frequently Asked Questions

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) posted its quarterly earnings results on Monday, March, 27th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.03.

Reneo Pharmaceuticals (RPHM) raised $101 million in an IPO on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/27/2023
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
-17.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-77,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.66 per share
Price / Book
0.68

Miscellaneous

Free Float
27,439,000
Market Cap
$60.84 million
Optionable
Optionable
Beta
0.21
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:RPHM) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners